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Lats1 is a tumor suppressor gene that was studied exten-
sively in Drosophila melangaster. Several studies were done
to address the molecular pathway of Lats 1, yet several
roles in carcinogenesis are not elucidated. Lats1 is a ser-
ine/threonine kinase similar to human myotonic dystro-
phy kinase (Justice et al., 1995). Lats 1 is phosphorylated
in a cell cycle dependent manner and was shown to mod-
ulate CDC2 and cyclin A activity (Tao et al., 1999). Trans-
genic Lats1-/- mice develop soft-tissue sarcomas and
ovarian stromal cell tumours and sensitivity to carcino-
genic treatments (St John et al., 1999). Lats1 was shown to
play a crucial role in controlling mitosis progression by
forming a Lats1/zyxin complex on mitotic apparatus
(Hirota et al., 2000). Overexpression of LATS1 signifi-
cantly suppressed the human tumor cell growth in vitro
and tumorigenicity in vivo by either G2-M arrest or apop-
tosis (Yang et al., 2001). The kinase inactive Lats1
impaired the G1 tetraploidy checkpoint due absence of
p53 induction (Iida et al., 2004). Few clinical studies cor-
related the expression of Lats1, promoter methylation and
tumor progression. We previously correlated Lats 1 over-
expression with the transcription regulator CDP/Cux in
selected tumors (Siam et al., unpublished results). We are
currently correlating these findings in clinical samples to
investigate the differential expression of Lats1 in many
human carcinomas. The hypermethylation of the Lats1
promoter and how this correlates with regulation of Lats1
expression by CDP/Cux p110 and/or p75 isoforms is
under investigation. We have preliminary evidence sug-
gesting that Lats1 expression and methylation status of
the Lats1 promoter are distinct in selected cancers. Addi-
tionally, we are suggesting the use of Lats1 expression and
the methylation status as prognostic marker for selected
tumors.
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